These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 31302895)

  • 1. Multimodal Analysis of FDA Drug Safety Communications: Lessons from Zolpidem.
    Kesselheim AS; Sinha MS; Campbell EG; Schneeweiss S; Rausch P; Lappin BM; Zhou EH; Avorn J; Dal Pan GJ
    Drug Saf; 2019 Nov; 42(11):1287-1295. PubMed ID: 31302895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patients' Knowledge of Key Messaging in Drug Safety Communications for Zolpidem and Eszopiclone: A National Survey.
    Kesselheim AS; Sinha MS; Rausch P; Lu Z; Tessema FA; Lappin BM; Zhou EH; Dal Pan GJ; Zwanziger L; Ramanadham A; Loughlin A; Enger C; Avorn J; Campbell EG
    J Law Med Ethics; 2019 Sep; 47(3):430-441. PubMed ID: 31560634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient and Physician Perceptions of Drug Safety Information for Sleep Aids: A Qualitative Study.
    Kesselheim AS; McGraw SA; Dejene SZ; Rausch P; Dal Pan GJ; Lappin BM; Zhou EH; Avorn J; Campbell EG
    Drug Saf; 2017 Jun; 40(6):531-542. PubMed ID: 28247279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Media Coverage of FDA Drug Safety Communications about Zolpidem: A Quantitative and Qualitative Analysis.
    Woloshin S; Schwartz LM; Dejene S; Rausch P; Dal Pan GJ; Zhou EH; Kesselheim AS
    J Health Commun; 2017 May; 22(5):365-372. PubMed ID: 28339323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methodological approaches to evaluate the impact of FDA drug safety communications.
    Kesselheim AS; Campbell EG; Schneeweiss S; Rausch P; Lappin BM; Zhou EH; Seeger JD; Brownstein JS; Woloshin S; Schwartz LM; Toomey T; Dal Pan GJ; Avorn J
    Drug Saf; 2015 Jun; 38(6):565-75. PubMed ID: 25968811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FDA drug safety communications: a narrative review and clinical considerations for older adults.
    Marcum ZA; Vande Griend JP; Linnebur SA
    Am J Geriatr Pharmacother; 2012 Aug; 10(4):264-71. PubMed ID: 22683398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Social Media Impact of the Food and Drug Administration's Drug Safety Communication Messaging About Zolpidem: Mixed-Methods Analysis.
    Sinha MS; Freifeld CC; Brownstein JS; Donneyong MM; Rausch P; Lappin BM; Zhou EH; Dal Pan GJ; Pawar AM; Hwang TJ; Avorn J; Kesselheim AS
    JMIR Public Health Surveill; 2018 Jan; 4(1):e1. PubMed ID: 29305342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Responsiveness of Veterans Affairs Health Care System to Zolpidem Safety Warnings.
    Kim HM; Gerlach LB; Yosef M; Stano C; Conroy DA; Valenstein M; Pfeiffer PN; Sales AE; Zivin K
    J Clin Sleep Med; 2018 Jul; 14(7):1135-1141. PubMed ID: 29991420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of eszopiclone, zaleplon, or zolpidem with complex sleep behaviors resulting in serious injuries, including death.
    Harbourt K; Nevo ON; Zhang R; Chan V; Croteau D
    Pharmacoepidemiol Drug Saf; 2020 Jun; 29(6):684-691. PubMed ID: 32323442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of a US Food and Drug Administration Drug Safety Communication on Zolpidem Dosing: An Observational Retrospective Cohort.
    Harward JL; Clinard VB; Jiroutek MR; Lingerfeldt BH; Muzyk AJ
    Prim Care Companion CNS Disord; 2015; 17(2):. PubMed ID: 26644946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in emergency department visits for zolpidem-attributed adverse drug reactions after FDA Drug Safety Communications.
    Geller AI; Zhou EH; Budnitz DS; Lovegrove MC; Dal Pan GJ
    Pharmacoepidemiol Drug Saf; 2020 Mar; 29(3):352-356. PubMed ID: 32483401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in prescribing and healthcare resource utilization after FDA Drug Safety Communications involving zolpidem-containing medications.
    Kesselheim AS; Donneyong M; Dal Pan GJ; Zhou EH; Avorn J; Schneeweiss S; Seeger JD
    Pharmacoepidemiol Drug Saf; 2017 Jun; 26(6):712-721. PubMed ID: 28449404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prescription Medications for the Treatment of Insomnia and Risk of Suicide Attempt: a Comparative Safety Study.
    Lavigne JE; Hur K; Kane C; Au A; Bishop TM; Pigeon WR
    J Gen Intern Med; 2019 Aug; 34(8):1554-1563. PubMed ID: 31161572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk evaluation and mitigation strategies (REMS): educating the prescriber.
    Nicholson SC; Peterson J; Yektashenas B
    Drug Saf; 2012 Feb; 35(2):91-104. PubMed ID: 22171604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New Drug Postmarketing Requirements and Commitments in the US: A Systematic Review of the Evidence.
    Moneer O; Brown BL; Avorn J; Darrow JJ; Mitra-Majumdar M; Joyce KW; Ross M; Pham C; Kesselheim AS
    Drug Saf; 2022 Apr; 45(4):305-318. PubMed ID: 35182362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unapproved prescription cough, cold, and allergy drug products: recent US Food and Drug Administration regulatory action on unapproved cough, cold, and allergy medications.
    Ostroff C; Lee CE; McMeekin J
    Chest; 2011 Aug; 140(2):295-300. PubMed ID: 21813527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Zolpidem and Gender: Are Women Really At Risk?
    Greenblatt DJ; Harmatz JS; Roth T
    J Clin Psychopharmacol; 2019; 39(3):189-199. PubMed ID: 30939589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FDA safety actions for antidiabetic drugs marketed in the US, 1980-2015.
    Kwon CS; Seoane-Vazquez E; Rodriguez-Monguio R
    Int J Risk Saf Med; 2016; 28(4):197-211. PubMed ID: 28582876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-market drug safety evidence sources: an analysis of FDA drug safety communications.
    Ishiguro C; Hall M; Neyarapally GA; Dal Pan G
    Pharmacoepidemiol Drug Saf; 2012 Oct; 21(10):1134-6. PubMed ID: 23033257
    [No Abstract]   [Full Text] [Related]  

  • 20. Development times, clinical testing, postmarket follow-up, and safety risks for the new drugs approved by the US food and drug administration: the class of 2008.
    Moore TJ; Furberg CD
    JAMA Intern Med; 2014 Jan; 174(1):90-5. PubMed ID: 24166236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.